CSIMarket
 
Maravai Lifesciences Holdings Inc   (MRVI)
Other Ticker:  
 
 
Price: $7.7000 $0.39 5.335%
Day's High: $7.785 Week Perf: -0.65 %
Day's Low: $ 7.10 30 Day Perf: 49.51 %
Volume (M): 6,787 52 Wk High: $ 16.62
Volume (M$): $ 52,261 52 Wk Avg: $9.65
Open: $7.28 52 Wk Low: $4.52



 Market Capitalization (Millions $) 1,016
 Shares Outstanding (Millions) 132
 Employees 1,400
 Revenues (TTM) (Millions $) 420
 Net Income (TTM) (Millions $) 59
 Cash Flow (TTM) (Millions $) -38
 Capital Exp. (TTM) (Millions $) 55

Maravai Lifesciences Holdings Inc
Maravai Lifesciences Holdings Inc is a global life sciences company that develops and provides critical products and services to the biopharmaceutical, diagnostic, and broader life sciences industries. The company was founded in 2014 and is headquartered in San Diego, California, United States.

The company operates through two business segments: Contract Development & Manufacturing Organization (CDMO) and Life Sciences.

The CDMO segment provides development and manufacturing services for gene therapy and vaccine products, as well as diagnostic and other biologics products. Its services include process development, cell line development, clinical and commercial manufacture, and testing and analytics.

The Life Sciences segment includes three business units: Genomics, Diagnostics, and Protein Sciences. The Genomics unit provides nucleic acid isolation and purification products, as well as other sample collection and preparation products for genetic sequencing applications. The Diagnostics unit develops and manufactures an array of diagnostic kits and reagents, and also provides custom contract development services. The Protein Sciences unit provides research and diagnostic tools for protein analysis.

Maravai has a global presence, with facilities in the United States, Europe, and Asia-Pacific. The company's clients include leading biopharmaceutical, research, academic and diagnostic organizations.

The company has been experiencing significant growth over the past few years, driven by strong demand for its products and services, as well as its focus on innovation and strategic acquisitions. In September 2020, Maravai completed its initial public offering (IPO), raising $62 billion USD in gross proceeds.

Overall, Maravai Lifesciences Holdings Inc is a highly respected and innovative company in the life sciences industry, dedicated to delivering high-quality, critical products and services to its clients worldwide.


   Company Address: 10770 Wateridge Circle San Diego 92121 CA
   Company Phone Number: 546-0004   Stock Exchange / Ticker: NASDAQ MRVI
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

TriLink BioTechnologies' CleanCap Technology: Empowering the Next Generation of mRNA Therapeutics

Published Wed, Feb 21 2024 8:58 PM UTC

In recent years, mRNA-based therapeutics have emerged as a transformative approach in the field of biopharmaceutics, offering promising opportunities for the treatment of various diseases. Among the key players driving this innovation is TriLink BioTechnologies, a leading provider of custom nucleic acid-based technologies and solutions for the global life sciences community....

Maravai Lifesciences Holdings Inc

Maravai Lifesciences Holdings Inc Faces Financial Disaster in Q3 of 2023: Is there Hope for Recovery?

Despite a disastrous financial report for the period between July and September 2023, Maravai Lifesciences Holdings Inc (MRVI) remains optimistic about its future prospects. The company reported a significant decrease in revenue, with a negative growth rate of -65.04%, resulting in revenue of $66.87 million for the aforementioned period. The net loss per share also saw a substantial increase, reaching $-0.05, compared to the previous year.
This decline in revenue is in stark contrast to the overall performance of the Major Pharmaceutical Preparations industry, which witnessed a rise in top-line growth during the same period. In fact, the industry showed an increase of 2.973% in revenue, with a total of $68.91 million. Such a discrepancy raises concerns, and Maravai Lifesciences Holdings Inc should address these issues promptly.

Maravai Lifesciences Holdings Inc

Maravai Lifesciences Holdings Inc Faces Critical Fiscal Period as Revenue Declines by 71.6% in Financial Interval Ending June 30, 2023

Maravai Lifesciences Holdings Inc (MRVI), a major player in the pharmaceutical preparations industry, recently reported disappointing financial results for the interval ending June 30, 2023. During this period, revenue declined by a significant -71.609% to $68.91 million, and the net loss per share expanded to $-0.05. This is in contrast to the performance of the overall industry, which saw a 0.89% improvement in revenue during the second quarter of 2023 compared to the same period last year.
The decline in revenue for MRVI was also reflected in a sequential decrease of -12.795% from the previous reporting season, where revenue stood at $79.03 million. This negative trend is concerning for investors and analysts alike, as the company experienced a net deficit of $-11.943 million in the April to June 30, 2023 financial span, compared to a net income of $156.721 million in the corresponding reporting season a year before.






 

Maravai Lifesciences Holdings Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com